Clinical Therapeutics in Pregnancy
Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2011-01-01
|
| Series: | Journal of Biomedicine and Biotechnology |
| Online Access: | http://dx.doi.org/10.1155/2011/783528 |
| id |
doaj-670a3b9ecda24636b017a80f4cb5ef80 |
|---|---|
| record_format |
Article |
| spelling |
doaj-670a3b9ecda24636b017a80f4cb5ef802020-11-25T01:39:57ZengHindawi LimitedJournal of Biomedicine and Biotechnology1110-72431110-72512011-01-01201110.1155/2011/783528783528Clinical Therapeutics in PregnancyMaisa N. Feghali0Donald R. Mattison1Department of Obstetrics and Gynecology, Washington Hospital Center, Washington, DC 20010, USAEunice Kennedy Shriver National Institute of Child Health and Human Development , NIH, Bethesda, MD 10892, USAMost drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the practitioner treats the pregnant woman with the same dose recommended for use in adults (typically men) or may decide not to treat the disease at all. However, is the choice of not treating a woman during pregnancy better than dealing with the challenges which accompany treatment? This paper, which summarizes metabolic and physiologic changes induced by pregnancy, illustrates that standard adult dosing is likely to be incorrect during pregnancy.http://dx.doi.org/10.1155/2011/783528 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Maisa N. Feghali Donald R. Mattison |
| spellingShingle |
Maisa N. Feghali Donald R. Mattison Clinical Therapeutics in Pregnancy Journal of Biomedicine and Biotechnology |
| author_facet |
Maisa N. Feghali Donald R. Mattison |
| author_sort |
Maisa N. Feghali |
| title |
Clinical Therapeutics in Pregnancy |
| title_short |
Clinical Therapeutics in Pregnancy |
| title_full |
Clinical Therapeutics in Pregnancy |
| title_fullStr |
Clinical Therapeutics in Pregnancy |
| title_full_unstemmed |
Clinical Therapeutics in Pregnancy |
| title_sort |
clinical therapeutics in pregnancy |
| publisher |
Hindawi Limited |
| series |
Journal of Biomedicine and Biotechnology |
| issn |
1110-7243 1110-7251 |
| publishDate |
2011-01-01 |
| description |
Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the practitioner treats the pregnant woman with the same dose recommended for use in adults (typically men) or may decide not to treat the disease at all. However, is the choice of not treating a woman during pregnancy better than dealing with the challenges which accompany treatment? This paper, which summarizes metabolic and physiologic changes induced by pregnancy, illustrates that standard adult dosing is likely to be incorrect during pregnancy. |
| url |
http://dx.doi.org/10.1155/2011/783528 |
| work_keys_str_mv |
AT maisanfeghali clinicaltherapeuticsinpregnancy AT donaldrmattison clinicaltherapeuticsinpregnancy |
| _version_ |
1725048123511799808 |